MustGrow Biologics Profit Margin

MustGrow Biologics (MGROF) currently reports a profit margin of -174.4% as of June 2026. That compares with -80.0% in the prior-year period — down 118.0% year over year. That is below the sector sector average of 13.2%. Use the charts on this page to explore MustGrow Biologics's profit margin history and peer comparisons.

MustGrow Biologics's profit margin decreased from -80.0% to -174.4% — a 118.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

MustGrow Biologics's profit margin of -174.4% is lower than the its sector sector average of 13.2%. That is roughly 1421.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but MustGrow Biologics's current -174.4% should be judged against industry norms (sector average: 13.2%) and against MGROF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -174.4%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 13.2%. From there, open related valuation or income-statement pages for MustGrow Biologics, and consider following MGROF for alerts when major investors trade the stock.